Cancer Vaccines Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Clinical Trials
• Forums

Vvax001 Cancer Vaccine in Premalignant Cervical Lesions - Phase II
Conditions:   CIN3;   Cervical Intraepithelial Neoplasia;   Cervical Intraepithelial Neoplasia Grade 3;   HPV 16 Infection Intervention:   Biological: Vvax001 therapeutic cancer vaccine Sponsors:   University Medical Center Groningen;   Dutch Cancer Society;   ViciniVax B.V Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials

Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer
Conditions:   Pancreatic Ductal Adenocarcinoma;   Refractory Non-Small Cell Lung Cancer Interventions:   Drug: Daratumumab;   Biological: KRAS vaccine;   Drug: Nivolumab Sponsors:   Georgetown University;   Bristol-Myers Squibb;   Janssen, LP;   Targovax ASA Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials

Vvax001 Cancer Vaccine in Premalignant Cervical Lesions - Phase II
Conditions:   CIN3;   Cervical Intraepithelial Neoplasia;   Cervical Intraepithelial Neoplasia Grade 3;   HPV 16 Infection Intervention:   Biological: Vvax001 therapeutic cancer vaccine Sponsors:   University Medical Center Groningen;   Dutch Cancer Society;   ViciniVax B.V Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials

Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer
Conditions:   Pancreatic Ductal Adenocarcinoma;   Refractory Non-Small Cell Lung Cancer Interventions:   Drug: Daratumumab;   Biological: KRAS vaccine;   Drug: Nivolumab Sponsors:   Georgetown University;   Bristol-Myers Squibb;   Janssen, LP;   Targovax ASA Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials

Vvax001 Cancer Vaccine in Premalignant Cervical Lesions - Phase II
Conditions:   CIN3;   Cervical Intraepithelial Neoplasia;   Cervical Intraepithelial Neoplasia Grade 3;   HPV 16 Infection Intervention:   Biological: Vvax001 therapeutic cancer vaccine Sponsors:   University Medical Center Groningen;   Dutch Cancer Society;   ViciniVax B.V Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials

Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer
Conditions:   Pancreatic Ductal Adenocarcinoma;   Refractory Non-Small Cell Lung Cancer Interventions:   Drug: Daratumumab;   Biological: KRAS vaccine;   Drug: Nivolumab Sponsors:   Georgetown University;   Bristol-Myers Squibb;   Janssen, LP;   Targovax ASA Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials

Vvax001 Cancer Vaccine in Premalignant Cervical Lesions - Phase II
Conditions:   CIN3;   Cervical Intraepithelial Neoplasia;   Cervical Intraepithelial Neoplasia Grade 3;   HPV 16 Infection Intervention:   Biological: Vvax001 therapeutic cancer vaccine Sponsors:   University Medical Center Groningen;   Dutch Cancer Society;   ViciniVax B.V Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials

Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer
Conditions:   Pancreatic Ductal Adenocarcinoma;   Refractory Non-Small Cell Lung Cancer Interventions:   Drug: Daratumumab;   Biological: KRAS vaccine;   Drug: Nivolumab Sponsors:   Georgetown University;   Bristol-Myers Squibb;   Janssen, LP;   Targovax ASA Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials

Vvax001 Cancer Vaccine in Premalignant Cervical Lesions - Phase II
Conditions:   CIN3;   Cervical Intraepithelial Neoplasia;   Cervical Intraepithelial Neoplasia Grade 3;   HPV 16 Infection Intervention:   Biological: Vvax001 therapeutic cancer vaccine Sponsors:   University Medical Center Groningen;   Dutch Cancer Society;   ViciniVax B.V Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials

Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer
Conditions:   Pancreatic Ductal Adenocarcinoma;   Refractory Non-Small Cell Lung Cancer Interventions:   Drug: Daratumumab;   Biological: KRAS vaccine;   Drug: Nivolumab Sponsors:   Georgetown University;   Bristol-Myers Squibb;   Janssen, LP;   Targovax ASA Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials

Vvax001 Cancer Vaccine in Premalignant Cervical Lesions - Phase II
Conditions:   CIN3;   Cervical Intraepithelial Neoplasia;   Cervical Intraepithelial Neoplasia Grade 3;   HPV 16 Infection Intervention:   Biological: Vvax001 therapeutic cancer vaccine Sponsors:   University Medical Center Groningen;   Dutch Cancer Society;   ViciniVax B.V Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials

Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer
Conditions:   Pancreatic Ductal Adenocarcinoma;   Refractory Non-Small Cell Lung Cancer Interventions:   Drug: Daratumumab;   Biological: KRAS vaccine;   Drug: Nivolumab Sponsors:   Georgetown University;   Bristol-Myers Squibb;   Janssen, LP;   Targovax ASA Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials

Vvax001 Cancer Vaccine in Premalignant Cervical Lesions - Phase II
Conditions:   CIN3;   Cervical Intraepithelial Neoplasia;   Cervical Intraepithelial Neoplasia Grade 3;   HPV 16 Infection Intervention:   Biological: Vvax001 therapeutic cancer vaccine Sponsors:   University Medical Center Groningen;   Dutch Cancer Society;   ViciniVax B.V Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials

Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer
Conditions:   Pancreatic Ductal Adenocarcinoma;   Refractory Non-Small Cell Lung Cancer Interventions:   Drug: Daratumumab;   Biological: KRAS vaccine;   Drug: Nivolumab Sponsors:   Georgetown University;   Bristol-Myers Squibb;   Janssen, LP;   Targovax ASA Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials

A Phase 0 Study of EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
Condition:   Colo-rectal Cancer Interventions:   Biological: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine;   Drug: Leucovorin;   Drug: Oxaliplatin;   Drug: Fluorouracil;   Biological: Bevacizumab;   Drug: Irinotecan;   Biological: Cetuximab;   Procedure: Metastasectomy;   Procedure: Biospecimen collection Sponsor:   Roswell Park Cancer Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 25, 2023 Category: Research Source Type: clinical trials